Novocure Ownership
| NVCR Stock | USD 21.00 0.24 1.13% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 107.7 M | Current Value 108.2 M | Avarage Shares Outstanding 92.5 M | Quarterly Volatility 21.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Novocure |
Novocure Stock Ownership Analysis
About 86.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 721.15. Novocure recorded a loss per share of 1.39. The entity had not issued any dividends in recent years. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. NovoCure operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people. To find out more about Novocure contact Asaf Danziger at 44 15 3475 6700 or learn more at https://www.novocure.com.Besides selling stocks to institutional investors, Novocure also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Novocure's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Novocure's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Novocure Quarterly Liabilities And Stockholders Equity |
|
Novocure Insider Trades History
About 10.0% of Novocure are currently held by insiders. Unlike Novocure's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Novocure's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Novocure's insider trades
Novocure Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Novocure is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Novocure backward and forwards among themselves. Novocure's institutional investor refers to the entity that pools money to purchase Novocure's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Baillie Gifford & Co Limited. | 2024-12-31 | 1.2 M | Balyasny Asset Management Llc | 2024-12-31 | 1.1 M | Federated Hermes Inc | 2024-09-30 | 997.4 K | Goldman Sachs Group Inc | 2024-12-31 | 941.5 K | Voloridge Investment Management, Llc | 2024-12-31 | 870.2 K | Charles Schwab Investment Management Inc | 2024-12-31 | 836.2 K | Jpmorgan Chase & Co | 2024-09-30 | 827.8 K | Palo Alto Investors, Llc | 2024-12-31 | 814.2 K | Millennium Management Llc | 2024-12-31 | 735.2 K | Fmr Inc | 2024-12-31 | 16.2 M | Blackrock Inc | 2024-12-31 | 13 M |
Novocure Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Novocure insiders, such as employees or executives, is commonly permitted as long as it does not rely on Novocure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Novocure insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Novocure Outstanding Bonds
Novocure issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Novocure uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Novocure bonds can be classified according to their maturity, which is the date when Novocure has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Novocure Corporate Filings
F4 | 15th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 6th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 17th of December 2024 An amendment to a previously filed Form 8-K | ViewVerify |
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.